Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks [Yahoo! Finance]
Athira Pharma, Inc. (ATHA)
Company Research
Source: Yahoo! Finance
A -0.08 change in GST (the Global Statistical Test, a combination of results from measures of cognition (ADAS-Cog11) and function (ADCS-ADL23) favoring fosgonimeton that did not reach statistical significance (p=0.70) The change in cognition from baseline, for which a decrease from baseline represents an improvement, was -0.39 for the placebo group and -1.09 for the fosgonimeton-treated group, a difference of -0.70 (p=0.35) favoring fosgonimeton. In the fosgonimeton-treated group, function increased (improved) by 0.65 versus a decline of -0.02 in placebo, although this difference did not meet statistical significance (p=0.61). In addition, data across protein pathology, inflammation, and neurodegeneration biomarkers showed directional improvements with fosgonimeton treatment. “These are not the results we hoped for, as the lack of clinical decline in the placebo group, combined with the short duration of the study, may have impacted the trial's ability to translate the effect
Show less
Read more
Impact Snapshot
Event Time:
ATHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHA alerts
High impacting Athira Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATHA
News
- Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business UpdatesGlobeNewswire
- Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 MeetingGlobeNewswire
- Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $5.00.MarketBeat
- Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative DiseasesGlobeNewswire
ATHA
Earnings
- 5/15/24 - Beat
ATHA
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- ATHA's page on the SEC website